SCHEMBL2931676

SCHEMBL2931676

O=C(Cc1c(-c2ccc(Cl)cc2)nc2ccc(Cl)cn12)c1cccs1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GABRA2 P47869 2/20 0.58
GABRB2 P47870 2/20 0.58
LMNA P02545 1/20 0.57
TSPO P30536 3/20 0.56
NR1I2 O75469 1/20 0.56
ABCB11 O95342 1/20 0.56
ALB P02768 1/20 0.56
ADORA3 P0DMS8 1/20 0.56
ADORA1 P30542 1/20 0.56
OPRM1 P35372 1/20 0.56
DRD3 P35462 1/20 0.56
OPRK1 P41145 1/20 0.56
PDE4D Q08499 1/20 0.56
KCNH2 Q12809 1/20 0.56
ALDH1A1 P00352 1/20 0.51
SLC2A2 P11168 2/20 0.51
SLC2A1 P11166 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2937747 0.94 LMNA (0.64) GABRA2GABRB2LMNATSPONR1I2
SCHEMBL8286559 0.89 KDM4E (0.55) GABRB2LMNASLC2A1
SCHEMBL2930958 0.84 GABRA1 (0.61) GABRA2GABRB2LMNATSPONR1I2
SCHEMBL8286546 0.83 TSPO (0.48) LMNATSPOALDH1A1
SCHEMBL8150 0.80 GABRA2 (0.70) GABRA2GABRB2TSPONR1I2ABCB11
SCHEMBL8288578 0.79 GABRA1 (0.53) GABRA2GABRB2LMNATSPOALB
SCHEMBL8286538 0.79 GABRA1 (0.49) GABRA2GABRB2LMNATSPONR1I2
SCHEMBL7261 0.78 GABRA2 (0.68) GABRA2GABRB2TSPONR1I2ABCB11
SCHEMBL2935478 0.77 LMNA (0.46) LMNA
SCHEMBL11069376 0.75 TSPO (0.75) GABRA2GABRB2LMNATSPONR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1682549-B1 IMIDAZO[1,2-A]PYRIDINE ANXIOLYTICS SEPRACOR INC (US) 2010-09-22 EP claimed
US-20080096867-A1 Imidazo[1,2-A] Pyridine Anxiolytics SEPRACOR INC. (US) 2008-04-24 US claimed
US-7148353-B2 Imidazo[1,2-a] pyridine anxiolytics SEPRACOR INC. (US) 2006-12-12 US claimed
US-20050171144-A1 Imidazo[1,2-a] pyridine anxiolytics SEPRACOR INC. (US) 2005-08-04 US claimed
EP-1682549-B1 IMIDAZO[1,2-A]PYRIDINE ANXIOLYTICS SEPRACOR INC (US) 2010-09-22 EP disclosed
EP-1682549-B1 IMIDAZO[1,2-A]PYRIDINE ANXIOLYTICS SEPRACOR INC (US) 2010-09-22 EP disclosed
US-7723324-B2 Imidazo[1,2-A]pyridine anxiolytics SEPRACOR, INC. (US) 2010-05-25 US disclosed
US-7723324-B2 Imidazo[1,2-A]pyridine anxiolytics SEPRACOR, INC. (US) 2010-05-25 US disclosed
US-7723324-B2 Imidazo[1,2-A]pyridine anxiolytics SEPRACOR, INC. (US) 2010-05-25 US disclosed
US-7566725-B2 Imidazo[1,2-A] pyridine anxiolytics SEPRACOR INC. (US) 2009-07-28 US disclosed
US-7566725-B2 Imidazo[1,2-A] pyridine anxiolytics SEPRACOR INC. (US) 2009-07-28 US disclosed
US-7566725-B2 Imidazo[1,2-A] pyridine anxiolytics SEPRACOR INC. (US) 2009-07-28 US disclosed
US-20070043074-A1 IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS SEPRACOR INC. (US) 2007-02-22 US disclosed
US-20070043074-A1 IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS SEPRACOR INC. (US) 2007-02-22 US disclosed
US-20070043074-A1 IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS SEPRACOR INC. (US) 2007-02-22 US disclosed
US-7148353-B2 Imidazo[1,2-a] pyridine anxiolytics SEPRACOR INC. (US) 2006-12-12 US disclosed
EP-1682549-A2 IMIDAZO[1,2-A]PYRIDINE ANXIOLYTICS Sepracor Inc. (US) 2006-07-26 EP disclosed
US-20050171144-A1 Imidazo[1,2-a] pyridine anxiolytics SEPRACOR INC. (US) 2005-08-04 US disclosed
WO-2005044818-A2 IMIDAZO[1,2-A]PYRIDINE ANXIOLYTICS SEPRACOR, INC. (US) 2005-05-19 WO disclosed
WO-2005044818-A2 IMIDAZO[1,2-A]PYRIDINE ANXIOLYTICS SEPRACOR, INC. (US) 2005-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043074-A1 IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS CNR1, CNR2, GABRA5 GABRA2 6/4885GABRB2 25/4885LMNA 2323/4885
US-20050171144-A1 Imidazo[1,2-a] pyridine anxiolytics CNR1, CNR2, GABRA5 GABRA2 6/4885GABRB2 25/4885LMNA 2323/4885
US-20080096867-A1 Imidazo[1,2-A] Pyridine Anxiolytics MTNR1B, ADORA2B, ADRA2B GABRA2 39/4885GABRB2 13/4885LMNA 1445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.